Phase 2
Completed N=34
Olanzapine in the Treatment of Patients With Anorexia Nervosa
Source: ClinicalTrials.gov NCT00260962 ↗Enrolled (actual)
34
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcomePrimary: Body Mass Index (BMI) (kg/m^2) — 19.66; 20.30; 19.66; 20.30 kg/m^2
Summary
The purpose of the study is to evaluate the efficacy of an anti-psychotic medication, Olanzapine, in achieving desired weight gain in patients identified as having Anorexia Nervosa, either restricting or binge/purge subtype. The study will also evaluate the possible beneficial effects of Olanzapine in reducing the severity of the obsessive and/or anxiety symptoms associated with this disorder.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Body Mass Index (BMI) (kg/m^2) |
19.66; 20.30; 19.66; 20.30 | — |
| SECONDARY Obsessions |
9.11; 11.06; 5.86; 6.54 | — |
Eligibility Criteria
Inclusion Criteria
- those who meet DSM IV criteria of Anorexia Nervosa- either restricting or binge/purge subtype
Exclusion Criteria
- patients who are actively self destructive and/or suicidal
- patients whose medical status is seriously compromised
- patients whose eating disorder is superimposed on a major psychiatric disorder such as schizophrenia, major affective disorders, dissociative disorder or an active substance abuse disorder.
Data sourced from ClinicalTrials.gov (NCT00260962). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.